Please help with biopsy results
Overwhelmed and scared.
====A. Right breast, R1 at 10:00, 3 cm from nipple, core biopsy
- Invasive ductal carcinoma (see comments)
- Focal ductal carcinoma in situ
B. Right axilla, rax at 10:00, 10-11 cm from nipple, core biopsy
- One lymph node, negative for carcinoma (0/1)
Value
INVASIVE CARCINOMA OF THE BREAST: Biopsy
INVASIVE CARCINOMA OF THE BREAST: BIOPSY - All Specimens
SPECIMEN
Procedure: Needle biopsy
Specimen Laterality: Right
TUMOR
Histologic Type: Invasive carcinoma of no special type (ductal)
Histologic Grade (Nottingham Histologic Score):
Glandular (Acinar) / Tubular Differentiation: Score 3
Nuclear Pleomorphism: Score 2
Mitotic Rate: Score 1
Overall Grade: Grade 2 (scores of 6 or 7)
Largest Invasive Focus in this Limited Biopsy Sample: 9.9 mm
Ductal Carcinoma In Situ (DCIS): Not identified
Lymphatic and / or Vascular Invasion: Not identified
Microcalcifications: Not identified
Breast Biomarker Reporting Template
BREAST BIOMARKER REPORTING TEMPLATE - All Specimens
Test(s) Performed:
Estrogen Receptor (ER) Status: Positive (greater than 10% of cells demonstrate nuclear positivity)
Percentage of Cells with Nuclear Positivity: 91-100%
Average Intensity of Staining: Strong
Test Type: Food and Drug Administration (FDA) cleared (test / vendor): Ventana Roche
Primary Antibody: SP1
Test(s) Performed:
Progesterone Receptor (PgR) Status: Positive
Percentage of Cells with Nuclear Positivity: 91-100%
Average Intensity of Staining: Strong
Test Type: Laboratory-developed test
Primary Antibody: 1E2
Test(s) Performed:
HER2 by Immunohistochemistry: Negative (Score 1+)
Test Type: Food and Drug Administration (FDA) cleared (test / vendor): Ventana Roche
Primary Antibody: 4B5
Test(s) Performed:
HER2 by in situ Hybridization: Negative (not amplified)
Method: Dual probe assay
Average Number of HER2 Signals per Cell: 1.9
Average Number of CEP17 Signals per Cell: 1.55
HER2 / CEP17 Ratio: 1.23
Test Type: Food and Drug Administration (FDA) cleared (test / vendor): Ventana HER2 Dual ISH DNA Probe Cocktail
Test(s) Performed: Ki-67
Ki-67 Percentage of Positive Nuclei: 20 %
Primary Antibody: MIB1
Cold Ischemia and Fixation Times: Meet requirements specified in latest version of the ASCO / CAP Guidelines
Testing Performed on Block Number(s): A1
METHODS
Fixative: Formalin
Image Analysis: Not performed
Comment(s): HER2 IHC was scored and reported according to ASCO/CAP Guidelines as negative, equivocal or positive for protein overexpression. As of 6/2024, in order to identify all cancers that may be eligible for evolving treatments targeting minimal levels of HER2 expression, samples reported as IHC 0 here exclude cases with any membranous staining (even if <10% of the sample). Samples with a reported score of IHC 1+ include all cases that have any incomplete membranous staining (both >10% and <10% of the sample).